COLOGNE, Germany, June 13 /PRNewswire/ -- The biotech company "amaxa GmbH"
today announced that it has successfully completed its second financing round,
thus obtaining funds of euro 13 million (US $ 11.6 million) for the two years
ahead.
New and leading investors include 3i Group Investments LP (United
Kingdom), other parties to this round being NRW Fonds GmbH (Germany) and
Technomedia Kapitalbeteiligungsgesellschaft Koln mbH (Germany). First-round
investors Earlybird Venture Capital (Germany) and Technologie
Beteiligungsgesellschaft mbH der Deutschen Ausgleichsbank (Germany) have also
engaged in the new round.
"We are impressed by the strong management, the innovative technology and
the high-growth business plan," commented Herbert Seggewiss, Investment
Director 3i.
"amaxa will use these funds to market Nucleofector(TM) technology and to
accelerate further pipeline projects," said CEO and Co-Founder Rainer
Christine. "This allows us to expand in the future." amaxa's first product
group, Nucleofector(TM) and Nucleofector(TM) Kits, is ready for market and
will be distributed internationally.
amaxa biosystems focuses on the development and the marketing of
innovative gene transfer technologies. One of amaxa's key competencies is the
non-viral gene transfer directly into the nucleus of primary cells and cell
lines by Nucleofector(TM) technology. This provides a rapid target gene
validation, accelerates the development of medical drugs and offers new
application for gene therapy. amaxa is a German biotech company based in
Cologne and founded in 1998. The company employs about 50 people.
Nucleofector(TM) technology:
amaxa provides the first highly efficient non-viral gene transfer method
for primary cells and for other hard-to-transfect cell lines.
Nucleofector(TM) technology guarantees unprecendented gene transfer
efficiencies for a non-viral method. What makes the Nucleofector(TM)
technology unique is its ability to directly transfer the DNA into the cell's
nucleus, i.e. nucleofect the cells, independent of cell division.
SOURCE amaxa GmbH
 back to top
Related links:
http://www.amaxa.com
CONTACT:
Steffen Reich, Corporate Communications,
+49-221-991-99-170, or fax, +49-2219-9199-111, or
Steffen.Reich@amaxa.com
|
